CONCLUSIONS
In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than with chemotherapy alone.
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Lynch Syndrome Ireland 